Bicalutamide

Generic Name
Bicalutamide
Brand Names
Casodex
Drug Type
Small Molecule
Chemical Formula
C18H14F4N2O4S
CAS Number
90357-06-5
Unique Ingredient Identifier
A0Z3NAU9DP
Background

Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor.

Indication

Bicalutamide is indicated in combination with a luteinizing hormone-releasing hormone (LHRH) agonist for the treatment of Stage D2 metastatic carcinoma of the prostate.

Associated Conditions
Metastatic stage D2 Prostatic carcinoma
Associated Therapies
-

Endocrine Therapy With or Without Cryoablation for Stage IV Prostate Cancer

First Posted Date
2015-11-26
Last Posted Date
2017-06-12
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
120
Registration Number
NCT02615223
Locations
🇨🇳

Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)

Phase 1
Active, not recruiting
Conditions
Interventions
First Posted Date
2015-11-16
Last Posted Date
2024-07-03
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
46
Registration Number
NCT02605486
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States

🇺🇸

Memorial Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States

and more 2 locations

Cryoablation Therapy or Radiotherapy Therapy for Stage III Prostate Cancer

First Posted Date
2015-11-16
Last Posted Date
2017-06-12
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
240
Registration Number
NCT02605226
Locations
🇨🇳

Tianjin Medical University Cancer Hospital, Tianjin, Tianjin, China

Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases

First Posted Date
2015-10-21
Last Posted Date
2022-07-11
Lead Sponsor
Ajjai Alva, MD
Target Recruit Count
16
Registration Number
NCT02582749
Locations
🇺🇸

University of Michigan Health System, Ann Arbor, Michigan, United States

🇺🇸

Clement J. Zablocki VA Medical Center, Milwaukee, Wisconsin, United States

🇺🇸

Illinois CancerCare, P. C., Peoria, Illinois, United States

and more 9 locations

Clinical Trial to Study Quality of Life in Prostate Cancer Patients by Randomizing Anti-androgen Versus Total Androgen Blockage Prior to Curative Intended Radiation Therapy

Phase 3
Completed
Conditions
Interventions
First Posted Date
2015-03-06
Last Posted Date
2015-03-06
Lead Sponsor
Karolinska University Hospital
Target Recruit Count
110
Registration Number
NCT02382094

Micro RNAs to Predict Response to Androgen Deprivation Therapy

First Posted Date
2015-02-19
Last Posted Date
2024-11-25
Lead Sponsor
Medical College of Wisconsin
Target Recruit Count
42
Registration Number
NCT02366494
Locations
🇺🇸

Froedtert Hospital, Milwaukee, Wisconsin, United States

AR-inhibitor Bicalutamide in Treating Patients With TNBC

First Posted Date
2015-02-03
Last Posted Date
2015-02-03
Lead Sponsor
Jinling Hospital, China
Target Recruit Count
60
Registration Number
NCT02353988

Bicalutamide as A Treatment in AR-positive Metastatic Triple-Negative Breast Cancer (mTNBC) Patients

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2015-01-28
Last Posted Date
2018-01-23
Lead Sponsor
Fudan University
Target Recruit Count
1
Registration Number
NCT02348281
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath